aTyr Pharma   Report issue

For profit Phase 2 Phase 3
Founded: San Diego CA United States (2005)

Organization Overview

First Clinical Trial
2014
NCT02239224
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

aTyr Pharma, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Efzofitimod (4 trials)

Drugs in Phase 2 Trials (1)

atyr1940 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Muscular Dystrophies (Phase 2)

Muscular Dystrophies, Limb-Girdle (Phase 2)

Muscular Dystrophy, Facioscapulohumeral (Phase 2)

Pneumonia (Phase 2)

Sarcoidosis (Phase 2)

Sarcoidosis, Pulmonary (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 2